Anthera Completes Special Protocol Assessment With FDA And Receives EMEA Scientific Advice On Development Path Toward Varespladib Approval
September 25th, 2008 by 
admin Anthera Pharmaceuticals declared they hit reached commendation with the U.S. Food and Drug Administration (FDA) on a Phase 3 prescript for varespladib (A-002) in accent thrombosis syndrome (ACS) low the FDA’s Special Protocol Assessment procedure. At the aforementioned time, the consort conventional Scientific Advice from the dweller Medicines Agency (EMEA) on Anthera’s dweller utilization strategy for varespladib.
Posted in Cardiology | 